{
  "main_header": {
    "sid": 1002696,
    "name": "Eiko Lifescience",
    "stock_name": "Eiko Lifescience",
    "full_name": "Eiko Lifesciences Ltd",
    "name_url": "stocks-analysis/eiko-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "50.25",
    "chg": -0.52,
    "chgp": "-1.02%",
    "dir": -1,
    "prev_price": "50.77",
    "mcapval": "71.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540204,
    "symbol": "",
    "ind_name": "Specialty Chemicals",
    "ind_code": 5,
    "indexname": "",
    "isin": "INE666Q01016",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "5.18 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eiko-lifescience-1002696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Eiko Lifesciences Forms Death Cross Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-forms-death-cross-signalling-potential-bearish-trend-3747054",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/EikoLifescience_dealthcross_3747054.png",
        "date": "2025-12-04 18:03:19",
        "description": "Eiko Lifesciences, a micro-cap player in the Specialty Chemicals sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory."
      },
      {
        "title": "Eiko Lifesciences: Analytical Reassessment Reflects Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-downgraded-to-sell-amid-mixed-financials-and-bearish-technicals-3740759",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/EikoLifescience_mojoScore_3740759.png",
        "date": "2025-12-02 08:58:57",
        "description": "Eiko Lifesciences, a player in the specialty chemicals sector, has undergone a revision in its market assessment following a detailed evaluation of its financial performance, valuation metrics, and technical indicators. The recent changes highlight a complex interplay of strong quarterly results contrasted with subdued long-term returns and evolving technical trends, prompting a nuanced view of the stock’s outlook."
      },
      {
        "title": "How has been the historical performance of Eiko Lifescience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-eiko-lifescience-3739370",
        "imagepath": "",
        "date": "2025-12-01 23:33:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Growth</strong></p>\n<p>Between March 2018 and March 2025, Eiko Lifescience’s net sales surged from ₹2.34 crores to ₹37.66 crores, marking a substantial increase that underscores the company’s expanding market presence. Total operating income mirrored this growth, rising from ₹2.34 crores to ₹37.66 crores over the same period. Despite this impressive top-line expansion, the company’s profitability experienced fluctuations. Operating profit before depreciation and interest (PBDIT) excluding other income was positive at ₹0.35 crores in March 2018 but turned negative in the years leading up to March 2020, reflecting operational challenges. However, by March 2025, the company returned to profitability with a PBDIT of ₹2.76 crores, supported by an additional ₹0.72 crores ..."
      },
      {
        "title": "Why is Eiko Lifescience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifescience-fallingrising-3734391",
        "imagepath": "",
        "date": "2025-11-28 00:42:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>The stock’s fall on 27-Nov is part of a short-term downward trend, with a one-week return of -3.37%, contrasting sharply with the Sensex’s modest gain of 0.10% over the same period. This divergence highlights Eiko Lifesciences’ relative weakness in the current market environment. Although the stock has managed a slight positive return of 1.14% over the past month, this is almost on par with the Sensex’s 1.11%, indicating that recent gains have been limited and not sufficient to offset broader losses.</p>\n<p>More concerning is the year-to-date (YTD) performance, where Eiko Lifesciences has declined by 18.25%, while the Sensex has risen by 9.70%. Over the last one year, the stock has fallen by 15.96%, whereas the benchmark index has appr..."
      },
      {
        "title": "Eiko Lifesciences Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-upgraded-to-hold-as-technicals-improve-amid-strong-quarterly-performance-3727920",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EikoLifescience_mojoScore_3727920.png",
        "date": "2025-11-25 08:56:13",
        "description": "Eiko Lifesciences, a player in the Specialty Chemicals sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. This shift comes amid a backdrop of strong quarterly results juxtaposed with subdued longer-term returns, prompting a nuanced reassessment of the company’s investment profile."
      },
      {
        "title": "Why is Eiko Lifescience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifescience-fallingrising-3709371",
        "imagepath": "",
        "date": "2025-11-17 23:37:58",
        "description": "As of 17-Nov, Eiko Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 53.10, reflecting a decrease of Rs 1.65 or 3.01%. The stock has underperformed its sector by 3.43% today and has been on a consecutive downward trend for the last two days, with a total drop of 3.47% in that period. Although the stock opened with a gain of 3.18% and reached an intraday high of Rs 56.49, it also touched a low of Rs 52.68, indicating significant volatility. The stock's performance over the past week shows a decline of 6.63%, while it has gained 4.63% over the past month. However, year-to-date, it has fallen by 15.36%, contrasting with the Sensex's gain of 8.72% during the same period. The stock is currently trading above its 200-day moving average but below its shorter-term moving averages, suggesting mixed signals regarding its trend. Additionally, there has been a notable decrease in investor p..."
      },
      {
        "title": "How has been the historical performance of Eiko Lifescience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-eiko-lifescience-3709158",
        "imagepath": "",
        "date": "2025-11-17 23:21:41",
        "description": "Answer:\nThe historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, culminating in a positive trend by March 2025.\n\nBreakdown:\nEiko Lifescience's net sales increased dramatically from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 2.34 Cr in March 2018 to 37.66 Cr in March 2025. The company's total expenditure also grew, but at a slower pace, from 1.99 Cr in March 2018 to 34.90 Cr in March 2025, leading to an operating profit (PBDIT) of 3.48 Cr in March 2025, a significant recovery from a loss of 4.50 Cr in March 2020. Profit before tax reached 2.92 Cr in March 2025, compared to a loss of 4.93 Cr in March 2020, and profit after tax improved to 2.18 Cr from a loss of 3.62 Cr in March 2020. The consolidated net profit for March 2025 was 2.11 Cr, a not..."
      },
      {
        "title": "Is Eiko Lifescience overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-eiko-lifescience-overvalued-or-undervalued-3700324",
        "imagepath": "",
        "date": "2025-11-14 08:12:40",
        "description": "As of 13 November 2025, Eiko Lifescience's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued. Key ratios include a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which suggests that the stock is relatively inexpensive compared to its growth prospects.\n\nIn comparison to its peers, Eiko Lifescience's PE ratio is lower than Bajaj Finance's 34.18 and significantly better than the life insurance sector's 11.18, which is categorized as very attractive. Additionally, while Bajaj Finserv is considered expensive with a PE of 33.91, Eiko's valuation appears more favorable. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year returns, the company's attractive valuation metrics suggest potential for future growth...."
      },
      {
        "title": "Why is Eiko Lifescience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifescience-fallingrising-3677613",
        "imagepath": "",
        "date": "2025-11-06 23:38:48",
        "description": "As of 06-Nov, Eiko Lifesciences Ltd's stock price is currently at Rs 57.49, reflecting a decline of Rs 4.54 or 7.32%. The stock has recently experienced a trend reversal, falling after four consecutive days of gains. Although it opened with a gain of 3.58% today and reached an intraday high of Rs 64.25, it also touched a low of Rs 57.03, indicating high volatility with an intraday fluctuation of 5.95%. The stock has outperformed the sector over the past week and month, with returns of +9.13% and +12.24%, respectively, but it has underperformed today by 6.49%. Additionally, Eiko Lifesciences is trading above all its moving averages, and there has been a significant increase in investor participation, with delivery volume rising by 408.71% compared to the five-day average.\n\nIn the broader market context, while Eiko Lifesciences has shown strong short-term performance relative to the Sensex, which declined by ..."
      }
    ],
    "total": 464,
    "sid": "1002696",
    "stock_news_url": "https://www.marketsmojo.com/news/eiko-lifesciences-1002696"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Nov-2025",
      "details": "Newspaper Publication for un-audited Financials Results of the Company for the quarter ended on 30th September 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 31St October 2025",
      "datetime": "31-Oct-2025",
      "details": "Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and amendments thereto this is to inform that the Meeting of the Board of Directors of the Company held today i.e. on Friday 31st October 2025 Board inter-alia considered and approved Un-Audited Financial Results (Standalone & Consolidated basis) for the Quarter and Half Year ended 30th September 2025 along with Limited Review Report The Meeting was commenced at 04: 45 PM and concluded at 5:30 PM.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Meeting Scheduled On Friday 31St October 2025",
      "datetime": "17-Oct-2025",
      "details": "Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated basis) for quarter and half year ended on 30th September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has declared <strong>2%</strong> dividend, ex-date: 20 Sep 17",
          "dt": "2017-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has announced <strong>2:3</strong> rights issue, ex-date: 07 Jul 23",
          "dt": "2023-07-07",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Eiko Lifesciences Forms Death Cross Signalling Potential Bearish Trend

2025-12-04 18:03:19

Eiko Lifesciences, a micro-cap player in the Specialty Chemicals sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory.

Read More

Eiko Lifesciences: Analytical Reassessment Reflects Mixed Financial and Technical Signals

2025-12-02 08:58:57

Eiko Lifesciences, a player in the specialty chemicals sector, has undergone a revision in its market assessment following a detailed evaluation of its financial performance, valuation metrics, and technical indicators. The recent changes highlight a complex interplay of strong quarterly results contrasted with subdued long-term returns and evolving technical trends, prompting a nuanced view of the stock’s outlook.

Read More

How has been the historical performance of Eiko Lifescience?

2025-12-01 23:33:04

Revenue and Profitability Growth

Between March 2018 and March 2025, Eiko Lifescience’s net sales surged from ₹2.34 crores to ₹37.66 crores, marking a substantial increase that underscores the company’s expanding market presence. Total operating income mirrored this growth, rising from ₹2.34 crores to ₹37.66 crores over the same period. Despite this impressive top-line expansion, the company’s profitability experienced fluctuations. Operating profit before depreciation and interest (PBDIT) excluding other income was positive at ₹0.35 crores in March 2018 but turned negative in the years leading up to March 2020, reflecting operational challenges. However, by March 2025, the company returned to profitability with a PBDIT of ₹2.76 crores, supported by an additional ₹0.72 crores ...

Read More

Why is Eiko Lifescience falling/rising?

2025-11-28 00:42:57

Recent Price Movement and Market Context

The stock’s fall on 27-Nov is part of a short-term downward trend, with a one-week return of -3.37%, contrasting sharply with the Sensex’s modest gain of 0.10% over the same period. This divergence highlights Eiko Lifesciences’ relative weakness in the current market environment. Although the stock has managed a slight positive return of 1.14% over the past month, this is almost on par with the Sensex’s 1.11%, indicating that recent gains have been limited and not sufficient to offset broader losses.

More concerning is the year-to-date (YTD) performance, where Eiko Lifesciences has declined by 18.25%, while the Sensex has risen by 9.70%. Over the last one year, the stock has fallen by 15.96%, whereas the benchmark index has appr...

Read More

Eiko Lifesciences Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-11-25 08:56:13

Eiko Lifesciences, a player in the Specialty Chemicals sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. This shift comes amid a backdrop of strong quarterly results juxtaposed with subdued longer-term returns, prompting a nuanced reassessment of the company’s investment profile.

Read More

Why is Eiko Lifescience falling/rising?

2025-11-17 23:37:58

As of 17-Nov, Eiko Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 53.10, reflecting a decrease of Rs 1.65 or 3.01%. The stock has underperformed its sector by 3.43% today and has been on a consecutive downward trend for the last two days, with a total drop of 3.47% in that period. Although the stock opened with a gain of 3.18% and reached an intraday high of Rs 56.49, it also touched a low of Rs 52.68, indicating significant volatility. The stock's performance over the past week shows a decline of 6.63%, while it has gained 4.63% over the past month. However, year-to-date, it has fallen by 15.36%, contrasting with the Sensex's gain of 8.72% during the same period. The stock is currently trading above its 200-day moving average but below its shorter-term moving averages, suggesting mixed signals regarding its trend. Additionally, there has been a notable decrease in investor p...

Read More

How has been the historical performance of Eiko Lifescience?

2025-11-17 23:21:41

Answer: The historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, culminating in a positive trend by March 2025. Breakdown: Eiko Lifescience's net sales increased dramatically from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 2.34 Cr in March 2018 to 37.66 Cr in March 2025. The company's total expenditure also grew, but at a slower pace, from 1.99 Cr in March 2018 to 34.90 Cr in March 2025, leading to an operating profit (PBDIT) of 3.48 Cr in March 2025, a significant recovery from a loss of 4.50 Cr in March 2020. Profit before tax reached 2.92 Cr in March 2025, compared to a loss of 4.93 Cr in March 2020, and profit after tax improved to 2.18 Cr from a loss of 3.62 Cr in March 2020. The consolidated net profit for March 2025 was 2.11 Cr, a not...

Read More

Is Eiko Lifescience overvalued or undervalued?

2025-11-14 08:12:40

As of 13 November 2025, Eiko Lifescience's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued. Key ratios include a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which suggests that the stock is relatively inexpensive compared to its growth prospects. In comparison to its peers, Eiko Lifescience's PE ratio is lower than Bajaj Finance's 34.18 and significantly better than the life insurance sector's 11.18, which is categorized as very attractive. Additionally, while Bajaj Finserv is considered expensive with a PE of 33.91, Eiko's valuation appears more favorable. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year returns, the company's attractive valuation metrics suggest potential for future growth....

Read More

Why is Eiko Lifescience falling/rising?

2025-11-06 23:38:48

As of 06-Nov, Eiko Lifesciences Ltd's stock price is currently at Rs 57.49, reflecting a decline of Rs 4.54 or 7.32%. The stock has recently experienced a trend reversal, falling after four consecutive days of gains. Although it opened with a gain of 3.58% today and reached an intraday high of Rs 64.25, it also touched a low of Rs 57.03, indicating high volatility with an intraday fluctuation of 5.95%. The stock has outperformed the sector over the past week and month, with returns of +9.13% and +12.24%, respectively, but it has underperformed today by 6.49%. Additionally, Eiko Lifesciences is trading above all its moving averages, and there has been a significant increase in investor participation, with delivery volume rising by 408.71% compared to the five-day average. In the broader market context, while Eiko Lifesciences has shown strong short-term performance relative to the Sensex, which declined by ...

Read More

View All News